Abstract Number: 1637 • ACR Convergence 2025
Sleep Quality as a Modifier of the Relationship Between Physical Activity and Functional Limitation in Adults with or at High Risk of Knee Osteoarthritis
Background/Purpose: Knee osteoarthritis (OA) is a leading cause of functional limitation (FL) in older adults. As there is no cure, treatment centers around symptom management,…Abstract Number: 1691 • ACR Convergence 2025
Standardizing DXA Screening in Childhood-Onset Systemic Lupus Erythematosus at A Single Center: A Quality Improvement Initiative Using a Decision-Tree Algorithm
Background/Purpose: Patients with childhood-onset systemic lupus erythematosus (cSLE) are at increased risk of low bone mineral density, with studies showing a 40% frequency of osteopenia (Lilleby,…Abstract Number: 1681 • ACR Convergence 2025
Lymphoma and Other Malignancies in Sjögren’s Disease: Incidence, Predictive Factors, and Mortality Outcomes.
Background/Purpose: The association between Sjögren’s disease (SjD) and non-Hodgkin lymphoma (NHL) is well established, although reported standardized incidence ratios (SIRs) vary considerably across studies. In…Abstract Number: 1720 • ACR Convergence 2025
Comparison of Mortality Trends in Adults with Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus: A 21-Year Analysis Using CDC WONDER DATABASE.
Background/Purpose: Systemic Lupus Erythematosus (SLE) and Cutaneous Lupus Erythematosus (CLE) are chronic autoimmune diseases with significant morbidity and mortality, collectively accounting for approximately 5,000 deaths…Abstract Number: 1718 • ACR Convergence 2025
Mortality and Hematological Adverse Events in Patients with Cancer Receiving Immune Checkpoint Inhibitors: Impact of Pre-existing Systemic Lupus Erythematosus
Background/Purpose: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, but their safety profile in patients with pre-existing autoimmune diseases, such as systemic lupus erythematosus (SLE),…Abstract Number: 1518 • ACR Convergence 2025
Efficacy and Safety of Anifrolumab in Discoid Lupus: A Meta-Analysis of the Literature
Background/Purpose: Anifrolumab, a monoclonal antibody targeting the type I interferon receptor, demonstrated clinical efficacy in systemic lupus erythematosus in the pivotal TULIP-2 trial¹. However, its…Abstract Number: 1530 • ACR Convergence 2025
The Renal Activity Index for Lupus Identifies and Predicts Complete Renal Remission or Absence of Kidney Involvement in Systemic Lupus Erythematosus
Background/Purpose: Effective, non-invasive disease activity and treatment response assessments are needed for patients with systemic lupus erythematosus (SLE), especially if associated with kidney disease, i.e.…Abstract Number: 1701 • ACR Convergence 2025
Gene Editing of HLA-Class II DRB1*04:01 at Position 82 Abrogates Binding of Citrullinated Arthritogenic Peptides and Collagen
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease with a strong genetic association to Class II HLA-DRB1*04:01. Presentation of arthritogenic peptides bound to DRB1*04:01…Abstract Number: 1663 • ACR Convergence 2025
Tocilizumab for acute exacerbation of rheumatic disease-related interstitial lung disease: A prospective real-world study
Background/Purpose: Acute exacerbation (AE) of rheumatic disease-related interstitial lung disease (RD-ILD) is a severe and potentially life-threatening condition, while there remains no clear consensus of…Abstract Number: 1726 • ACR Convergence 2025
Inflammatory arthritis immune related adverse events represent a unique autoimmune disease entity primarily driven by T cells, but likely not autoantibodies
Background/Purpose: The immunological basis of inflammatory arthritis (IA) immune related adverse event (irAE) following anti-PD-1/PD-L1 immune checkpoint inhibition (ICI) therapy is incompletely understood. The relationship…Abstract Number: 1729 • ACR Convergence 2025
The ERIN Registry: Real-World Data on Rheumatic Immune-Related Adverse Events from Immune Checkpoint Inhibitor Therapy
Background/Purpose: Immune checkpoint inhibitors (ICIs) are a mainstay of cancer immunotherapy. However, their increasing use has led to more immune-related adverse events (irAEs), including rheumatic…Abstract Number: 1540 • ACR Convergence 2025
Association of Hypoalbuminemia with Serious Infections in Systemic Lupus Erythematosus Patients Receiving Dialysis
Background/Purpose: Lupus nephritis, a key manifestation of systemic lupus erythematosus (SLE), can progress to end-stage kidney disease and increase patient burden. While patients with SLE…Abstract Number: 1650 • ACR Convergence 2025
Malondialdehyde-Acetaldehyde and Citrulline Modified Proteins are Overexpressed in Cardiac Tissues in Rheumatoid Arthritis-Associated Heart Failure and Mediate Endothelial Cell Dysfunction
Background/Purpose: Previous reports show that malondialdehyde-acetaldehyde (MAA) adducts are overexpressed in RA, especially in joint/lung tissues, and that they colocalize with citrulline (CIT). This is…Abstract Number: 1715 • ACR Convergence 2025
Spondyloarthritis and Psoriatic Arthritis Patients Under Immunosuppressive Conventional and Biologic DMARDs: Favorable Disease Safety and Attenuated Immunogenicity Following Recombinant Herpes Zoster Vaccination
Background/Purpose: Psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) patients are at increased risk for herpes zoster(HZ) due to impaired cell-mediated immunity associated with the underlying…Abstract Number: 1543 • ACR Convergence 2025
Low-Dose Aspirin Therapy in Patients with Type 2 Diabetes and Systemic Lupus Erythematosus: A Propensity-Matched Cohort Study
Background/Purpose: Patients with both Type 2 diabetes mellitus (T2DM) and systemic lupus erythematosus (SLE) face an increased risk of cardiovascular complications due to the compounding…
- « Previous Page
- 1
- …
- 123
- 124
- 125
- 126
- 127
- …
- 2607
- Next Page »